The claim that Dr. Liau filed a separate “ATL-DC” patent that differs from the one UCLA licensed to Northwest Biotherapeutics is inaccurate once you look closely at the filings. The UCLA Case No. 2015-341 patent is real, but it is not a different vaccine. It is a method patent that covers the use of an autologous tumor-lysate–pulsed dendritic-cell vaccine together with a PD-1 or PD-L1 checkpoint inhibitor for treating glioblastoma and related cancers. In plain language, it protects the combination treatment, not a new or separate cell product. The inventors are Dr. Linda Liau and Dr. Robert Prins of UCLA, and a European version of this patent, EP 3065772 B1, has already been granted.
The vaccine described inside that filing, the so-called “ATL-DC”, is the same underlying dendritic-cell product that Northwest Biotherapeutics licenses and commercializes as DCVax-L. The platform itself originated at UCLA, and NWBO holds the exclusive commercial license for its therapeutic use in brain cancers. The 2015-341 patent simply extends the platform by pairing it with checkpoint blockade therapy. So while the filing is new in its claims, the scientific foundation is exactly the same.
In fact, the patent has already been folded into NWBO’s intellectual-property network. Later continuations of the filing list NWBO’s own scientists, including Marnix Bosch and other affiliates such as Cognate BioServices and RevImmune, as co-applicants. That means the company either co-owns or holds an exclusive license to use the combination claims commercially. The invention did not remain a separate UCLA asset, it became part of the larger DCVax portfolio.
The two sets of patents occupy different but complementary layers of the same system. NWBO’s own patents describe how the dendritic cells are manufactured and matured—how to produce partially matured DCs that capture tumor antigens and trigger a strong Th1 immune response once injected. The UCLA 2015-341 patent focuses on how to use that same vaccine alongside a checkpoint inhibitor such as pembrolizumab or nivolumab. One protects the composition and manufacturing process; the other protects the therapeutic regimen. They work together rather than against each other.
When UCLA researchers refer to “ATL-DC” in academic studies, they’re describing the same vaccine that NWBO calls DCVax-L. The difference is only in setting. UCLA can make small research batches in its own cleanroom for investigator-initiated trials, such as the current pembrolizumab + ATL-DC trial for recurrent glioblastoma. Those are non-commercial academic productions. The commercial product (made in Advent BioServices’ GMP facilities under strict process control) is DCVax-L. The formulation and immune logic are identical; the labels and manufacturing oversight differ.
All the evidence points in one direction: the 2015-341 patent does not create a competing or unrelated therapy. It extends the DCVax platform by protecting its combination with checkpoint inhibitors, and Northwest Biotherapeutics has already secured the rights. The “academic” ATL-DC and the “commercial” DCVax-L are two phases of the same scientific lineage, the first born in a university lab, the second adapted for regulated manufacturing and global deployment.
And rather than weakening the company’s position, this actually strengthens it. The addition of 2015-341 means that NWBO now holds protection not just over the vaccine itself, but over the next generation of immunotherapy built upon it. The platform has evolved from a single-agent dendritic-cell vaccine to a full combinatorial architecture, where DCVax can be paired with PD-1 inhibitors, IL-7 cytokine boosters, or other modulators without losing exclusivity. In investment terms, that’s not dilution, it’s the expansion of the moat. UCLA’s continued involvement only underscores the scientific depth and legitimacy of the platform, while NWBO’s ownership of both the production patents and the combination rights locks in control of the entire field.
In short, there is no divergence between Dr. Liau’s patent and NWBO’s platform. They form one continuous intellectual property chain: the original autologous tumor-lysate dendritic vaccine invented at UCLA, its maturation and production optimized under NWBO’s patents, and now the combination therapy formally protected by UCLA’s 2015-341 filing with NWBO as partner. The notion that they represent different or competing vaccines is a misunderstanding of how academic discovery and commercial licensing interact. The 2015-341 case strengthens, rather than separates, the DCVax franchise, and in doing so, it reinforces the bullish thesis that NWBO owns the dendritic-cell future from laboratory bench to clinical deployment.
Bullish
Market Data 
Markets 
AI
